Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Post by davgroon Oct 20, 2022 12:49pm
260 Views
Post# 35036706

Just a Friendly Reminder...

Just a Friendly Reminder...If you haven't added our resident trolls to your IGNORE list, now is the time.

With ATE touching a new 52-week low today of C$0.54, on minimal trading volume, the trolls will be screaming that the "sky is falling". It may be happenning right now as I post this.

Anyone who is following the market and ATE will realize that small caps and biotechs are currently out of favour.  Good sound companies are seeing their stocks touching new 52-week lows as "risk-off" is the market catchphrase of the day.  The patient contrarian investor who can identify undervalued and oversold stocks will reap the rewards in the longterm.

So before you are overwhelmed with immature YouTube memes and angry tirades from penny-flipping trolls, do yourself a favour and "silence the noise".  I personally don't expect any market moving news from ATE until the new year.  If you add tax loss selling, an impending recession, and general market conditions, it is not surprising to see a slow downward drift in ATE's stock price.

If you believe in the science you may be rewarded in 2023.  If you are one of our trolls, you are invisible to me.  Scream and yell to your heart's content.

How do I ignore a Stockhouse User ?

GLTA 
<< Previous
Bullboard Posts
Next >>